Literature DB >> 7287903

Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs.

T Wasada, K McCorkle, V Harris, K Kawai, B Howard, R H Unger.   

Abstract

To determine whether gastric inhibitory polypeptide (GIP) promotes the clearance of chylomicron triglycerides (TG) from the circulation in dogs, chyle collected from donor dogs via a thoracic duct fistula was infused at a rate of 2 ml/min i.v. into normal recipient dogs during an infusion of either porcine GIP (1 microgram/kg per h) or saline as a control. In the GIP-infused dogs the rise in plasma TG was significantly below that of the control animals [mean peak of 36 +/- 4 mg/dl vs. 82 +/- 18 mg/dl (P less than 0.05)]. It is concluded that GIP exerts an effect upon the removal of chylomicron TG from the blood. The results suggest that GIP may play a physiologic role in the disposition of ingested fat.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7287903      PMCID： PMC370900          DOI： 10.1172/jci110335

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  9 in total

1.  Immunoassay of endogenous plasma insulin in man.

Authors:  R S YALOW; S A BERSON
Journal:  J Clin Invest       Date:  1960-07       Impact factor: 14.808

2.  Stimulation of insulin secretion by gastric inhibitory polypeptide in man.

Authors:  J Dupre; S A Ross; D Watson; J C Brown
Journal:  J Clin Endocrinol Metab       Date:  1973-11       Impact factor: 5.958

3.  Quantitative determination of serum triglycerides by the use of enzymes.

Authors:  G Bucolo; H David
Journal:  Clin Chem       Date:  1973-05       Impact factor: 8.327

4.  Release of pancreatic and gastric somatostatin-like immunoreactivity in response to the octapeptide of cholecystokinin, secretin gastric inhibitory polypeptide, and gastrin-17 in dogs.

Authors:  D Rouiller; V Schusdziarra; V Harris; R H Unger
Journal:  Endocrinology       Date:  1980-08       Impact factor: 4.736

5.  Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man.

Authors:  J M Falko; S E Crockett; S Cataland; E L Mazzaferri
Journal:  J Clin Endocrinol Metab       Date:  1975-08       Impact factor: 5.958

6.  Measurements of somatostatin-like immunoreactivity in plasma.

Authors:  V Harris; J M Conlon; C B Srikant; K McCorkle; V Schusdziarra; E Ipp; R H Unger
Journal:  Clin Chim Acta       Date:  1978-07-15       Impact factor: 3.786

7.  Gastric inhibitory polypeptide. Its physiologic release and insulinotropic action in the dog.

Authors:  R A Pederson; H E Schubert; J C Brown
Journal:  Diabetes       Date:  1975-12       Impact factor: 9.461

8.  The effects of triglyceride absorption upon glucagon, insulin, and gut glucagon-like immunoreactivity.

Authors:  I Böttger; R Dobbs; G R Faloona; R H Unger
Journal:  J Clin Invest       Date:  1973-10       Impact factor: 14.808

9.  Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes.

Authors:  R H Eckel; W Y Fujimoto; J D Brunzell
Journal:  Diabetes       Date:  1979-12       Impact factor: 9.461
  9 in total
  34 in total

1.  Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

Authors:  N Matikainen; S Mänttäri; A Schweizer; A Ulvestad; D Mills; B E Dunning; J E Foley; M-R Taskinen
Journal:  Diabetologia       Date:  2006-07-01       Impact factor: 10.122

2.  Gut triglyceride production.

Authors:  Xiaoyue Pan; M Mahmood Hussain
Journal:  Biochim Biophys Acta       Date:  2011-10-02

3.  The effect of anagliptin treatment on glucose metabolism and lipid metabolism, and oxidative stress in fasting and postprandial states using a test meal in Japanese men with type 2 diabetes.

Authors:  Hirokazu Kakuda; Junji Kobayashi; Masahiro Kakuda; Junichi Yamakawa; Noboru Takekoshi
Journal:  Endocrine       Date:  2014-08-13       Impact factor: 3.633

4.  Insulin-dependent inhibition of hepatic glycogenolysis by gastric inhibitory polypeptide (GIP) in perfused rat liver.

Authors:  H Hartmann; R Ebert; W Creutzfeldt
Journal:  Diabetologia       Date:  1986-02       Impact factor: 10.122

5.  Direct metabolic effects of gastric inhibitory polypeptide (GIP): dissociation at physiological levels of effects on insulin-stimulated fatty acid and glucose incorporation in rat adipose tissue.

Authors:  B Beck; J P Max
Journal:  Diabetologia       Date:  1986-01       Impact factor: 10.122

Review 6.  New developments in the incretin concept.

Authors:  W Creutzfeldt; R Ebert
Journal:  Diabetologia       Date:  1985-08       Impact factor: 10.122

7.  The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice.

Authors:  J Hsieh; C Longuet; C L Baker; B Qin; L M Federico; D J Drucker; K Adeli
Journal:  Diabetologia       Date:  2009-12-03       Impact factor: 10.122

8.  Gastric inhibitory polypeptide (GIP) hypersecretion in obesity depends on meal size and is not related to hyperinsulinemia.

Authors:  R Ebert; W Creutzfeldt
Journal:  Acta Diabetol Lat       Date:  1989 Jan-Mar

9.  Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans.

Authors:  Meena Asmar; Lene Simonsen; Sten Madsbad; Bente Stallknecht; Jens Juul Holst; Jens Bülow
Journal:  Diabetes       Date:  2010-06-14       Impact factor: 9.461

10.  Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice.

Authors:  Akiko Matsuyama-Yokono; Atsuo Tahara; Ryosuke Nakano; Yuka Someya; Masahiko Hayakawa; Masayuki Shibasaki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-02       Impact factor: 3.000
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.